Connie Marras

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6815322/publications.pdf

Version: 2024-02-01

165 papers	7,746 citations	57758 44 h-index	60623 81 g-index
168 all docs	168 docs citations	168 times ranked	8536 citing authors

#	Article	IF	Citations
1	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurology, The, 2008, 7, 583-590.	10.2	1,340
2	Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson Disease. JAMA Neurology, 2015, 72, 100.	9.0	272
3	Nonmotor features of Parkinson's disease subtypes. Movement Disorders, 2016, 31, 1095-1102.	3.9	254
4	<scp>N</scp>omenclature of genetic movement disorders: <scp>R</scp>ecommendations of the international <scp>P</scp>arkinson and movement disorder society task force. Movement Disorders, 2016, 31, 436-457.	3.9	228
5	Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 535-540.	2.2	217
6	Genotypeâ€Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review. Movement Disorders, 2018, 33, 730-741.	3.9	215
7	Parkinson's disease subtypes: lost in translation?. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 409-415.	1.9	181
8	Predicting Motor Decline and Disability in Parkinson Disease. Archives of Neurology, 2002, 59, 1724.	4.5	179
9	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Movement Disorders, 2018, 33, 208-218.	3.9	138
10	Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. JAMA Neurology, 2016, 73, 535.	9.0	136
11	Penetrance estimate of LRRK2 p.G2019S mutation in individuals of nonâ€Ashkenazi Jewish ancestry. Movement Disorders, 2017, 32, 1432-1438.	3.9	126
12	Predictors of deterioration in healthâ€related quality of life in Parkinson's disease: Results from the DATATOP trial. Movement Disorders, 2008, 23, 653-659.	3.9	122
13	Measuring mild cognitive impairment in patients with Parkinson's disease. Movement Disorders, 2013, 28, 626-633.	3.9	120
14	Genotypeâ€phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Movement Disorders, 2018, 33, 1857-1870.	3.9	120
15	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. Movement Disorders, 2017, 32, 1056-1065.	3.9	117
16	Environment, lifestyle, and Parkinson's disease: Implications for prevention in the next decade. Movement Disorders, 2019, 34, 801-811.	3.9	116
17	Cognitive impairment in Parkinsonâ€™s disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. Npj Parkinson's Disease, 2018, 4, 19.	5.3	110
18	Dietary fat intake, pesticide use, and Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 82-87.	2.2	108

#	Article	IF	Citations
19	Helicobacter pylori infection is associated with worse severity of Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 221-225.	2.2	107
20	Motor and nonmotor heterogeneity of LRRK2â€related and idiopathic Parkinson's disease. Movement Disorders, 2016, 31, 1192-1202.	3.9	102
21	Systematic Review of the Risk of Dementia and Chronic Cognitive Impairment After Mild Traumatic Brain Injury: Results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Archives of Physical Medicine and Rehabilitation, 2014, 95, S245-S256.	0.9	99
22	Regular Exercise, Quality of Life, and Mobility in Parkinsonâ€™s Disease: AÂLongitudinal Analysis of National Parkinson Foundation Quality Improvement Initiative Data. Journal of Parkinson's Disease, 2017, 7, 193-202.	2.8	92
23	Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations. Movement Disorders, 2004, 19, 22-28.	3.9	89
24	Cervical Myelopathy Caused by Hypoplasia of the Atlas: Two Case Reports and Review of the Literature. Neurosurgery, 1998, 43, 629-633.	1.1	86
25	Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5164-E5173.	7.1	83
26	Treatable inherited rare movement disorders. Movement Disorders, 2018, 33, 21-35.	3.9	79
27	Genotypeâ€“Phenotype Relations for Isolated Dystonia Genes: <scp>MDSGene</scp> Systematic Review. Movement Disorders, 2021, 36, 1086-1103.	3.9	74
28	Invited Article: Changing concepts in Parkinson disease. Neurology, 2008, 70, 1996-2003.	1.1	73
29	Understanding the Links Between Cardiovascular Disease and Parkinson's Disease. Movement Disorders, 2020, 35, 55-74.	3.9	71
30	Fixing the broken system of genetic locus symbols. Neurology, 2012, 78, 1016-1024.	1.1	70
31	Systematic Review of the Risk of Parkinson's Disease After Mild Traumatic Brain Injury: Results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Archives of Physical Medicine and Rehabilitation, 2014, 95, S238-S244.	0.9	68
32	Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimerâ€™s Disease and Parkinsonâ€™s Disease Affect Caregiver Mood and Burden. Frontiers in Aging Neuroscience, 2018, 10, 120.	3.4	64
33	Concordance for Parkinson's disease in twins: A 20â€year update. Annals of Neurology, 2019, 85, 600-605.	5.3	64
34	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. Parkinsonism and Related Disorders, 2018, 56, 102-106.	2.2	63
35	The genetic nomenclature of recessive cerebellar ataxias. Movement Disorders, 2018, 33, 1056-1076.	3.9	61
36	Inflammatory profile in LRRK2-associated prodromal and clinical PD. Journal of Neuroinflammation, 2016, 13, 122.	7.2	57

#	Article	IF	Citations
37	Parkinsonâ€™s Disease Subtypes: Critical Appraisal and Recommendations. Journal of Parkinson's Disease, 2021, 11, 395-404.	2.8	56
38	Dihydropyridine calcium channel blockers and the progression of parkinsonism. Annals of Neurology, 2012, 71, 362-369.	5.3	55
39	Launching the movement disorders society genetic mutation database (MDSGene). Movement Disorders, 2016, 31, 607-609.	3.9	54
40	Infection and Risk of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 31-43.	2.8	54
41	Environmental and occupational risk factors for progressive supranuclear palsy: Caseâ€control study. Movement Disorders, 2016, 31, 644-652.	3.9	53
42	The tools of the trade: A state of the art â€œHow to Assess Cognitionâ€•in the patient with Parkinson's disease. Movement Disorders, 2014, 29, 584-596.	3.9	52
43	Recent developments in drug-induced movement disorders: a mixed picture. Lancet Neurology, The, 2019, 18, 880-890.	10.2	52
44	Telemedicine in Parkinson's disease: A patient perspective at a tertiary care centre. Parkinsonism and Related Disorders, 2015, 21, 525-528.	2.2	50
45	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force â€“ An Update. Movement Disorders, 2022, 37, 905-935.	3.9	49
46	Appendectomy in mid and later life and risk of Parkinson's disease: A populationâ€based study. Movement Disorders, 2016, 31, 1243-1247.	3.9	48
47	The prodromal phase of leucineâ€rich repeat kinase 2â€“associated Parkinson disease: Clinical and imaging Studies. Movement Disorders, 2017, 32, 726-738.	3.9	48
48	Subtypes of Parkinson's disease. Current Opinion in Neurology, 2015, 28, 382-386.	3.6	47
49	Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 1087-1098.	2.8	46
50	<scp>Helicobacter pylori</scp> Eradication in Parkinson's Disease: A Randomized Placeboâ€Controlled Trial. Movement Disorders, 2020, 35, 2250-2260.	3.9	45
51	Detecting Mild Cognitive Deficits in <scp>P</scp>arkinson's <scp>D</scp>isease: <scp>C</scp>omparison of <scp>N</scp>europsychological <scp>T</scp>ests. Movement Disorders, 2018, 33, 1750-1759.	3.9	42
52	Clinical Parkinson disease subtyping does not predict pathology. Nature Reviews Neurology, 2019, 15, 189-190.	10.1	42
53	Therapy of Parkinson's Disease Subtypes. Neurotherapeutics, 2020, 17, 1366-1377.	4.4	42
54	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinsonâ€™s disease. Brain, 2017, 140, 1371-1383.	7.6	41

#	Article	IF	Citations
55	Initial cognitive changes in Parkinson's disease. Movement Disorders, 2018, 33, 511-519.	3.9	41
56	The Impact of <scp>COVID</scp>â€19 on Access to Parkinson's Disease Medication. Movement Disorders, 2020, 35, 2129-2133.	3.9	40
57	Cognitive Impairment in Parkinsonâ€™s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. Behavioral Sciences (Basel, Switzerland), 2021, 11, 74.	2.1	39
58	Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. British Journal of Clinical Pharmacology, 2016, 82, 461-472.	2.4	35
59	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. Neurology, 2018, 90, e2059-e2067.	1.1	35
60	Genotypeâ€“Phenotype Relations in Primary Familial Brain Calcification: Systematic <scp>MDSGene</scp> Review. Movement Disorders, 2021, 36, 2468-2480.	3.9	35
61	Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). Journal of Neuropathology and Experimental Neurology, 2018, 77, 793-802.	1.7	32
62	Risk of Parkinson's disease dementia related to level I MDS PDâ€MCI. Movement Disorders, 2019, 34, 430-435.	3.9	32
63	Lithium Use in Older Adults is Associated with Increased Prescribing of Parkinson Medications. American Journal of Geriatric Psychiatry, 2016, 24, 301-309.	1.2	31
64	Nonmotor Signs in Genetic Forms of Parkinson's Disease. International Review of Neurobiology, 2017, 133, 129-178.	2.0	31
65	Genomewide Association Studies of <scp>LRRK2</scp> Modifiers of Parkinson's Disease. Annals of Neurology, 2021, 90, 76-88.	5.3	30
66	Antipsychotics and Mortality in Parkinsonism. American Journal of Geriatric Psychiatry, 2012, 20, 149-158.	1.2	29
67	The relevance of pre-motor symptoms in Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2015, 15, 1205-1217.	2.8	29
68	Cerebrospinal fluid biomarkers and clinical features in leucineâ€rich repeat kinase 2 (LRRK2) mutation carriers. Movement Disorders, 2016, 31, 906-914.	3.9	29
69	Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and Healthy Controls. Frontiers in Neuroscience, 2019, 13, 1259.	2.8	29
70	Antipsychotic Use and Physical Morbidity in Parkinson Disease. American Journal of Geriatric Psychiatry, 2017, 25, 697-705.	1.2	28
71	Antipsychotic use in older adults with Parkinson's disease. Movement Disorders, 2007, 22, 319-323.	3.9	26
72	Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. Parkinsonism and Related Disorders, 2014, 20, 222-225.	2.2	25

#	Article	IF	Citations
73	Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinsonâ€™s Disease Research: The Fox Insight Cohort Experience. Journal of Parkinson's Disease, 2020, 10, 665-675.	2.8	25
74	Barriers and facilitators of communication about off periods in Parkinsonâ€™s disease: Qualitative analysis of patient, carepartner, and physician Interviews. PLoS ONE, 2019, 14, e0215384.	2.5	24
75	Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force. Movement Disorders, 2019, 34, 1602-1613.	3.9	23
76	22q11.2 Deletion Syndromeâ€“Associated Parkinson's Disease. Movement Disorders Clinical Practice, 2019, 6, 11-16.	1.5	22
77	Identifying drugs with diseaseâ€modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2020, 29, 864-872.	1.9	22
78	Genotypeâ€“Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. Movement Disorders, 2021, 36, 1499-1510.	3.9	22
79	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Movement Disorders, 2011, 26, 608-613.	3.9	20
80	Sequence of electrode implantation and outcome of deep brain stimulation for Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 859-863.	1.9	20
81	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, 503-510.	2.8	18
82	Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?. Parkinsonism and Related Disorders, 2019, 69, 34-39.	2.2	18
83	Parkinson's Disease, <scp>NOTCH3</scp> Genetic Variants, and White Matter Hyperintensities. Movement Disorders, 2020, 35, 2090-2095.	3.9	18
84	Video-based Parkinsonâ€™s disease assessments in a nationwide cohort of Fox Insight participants. Clinical Parkinsonism & Related Disorders, 2021, 4, 100094.	0.9	18
85	Initiating dopaminergic treatment in Parkinson's disease. Lancet, The, 2014, 384, 1164-1166.	13.7	17
86	Outcome measures for clinical trials in Parkinsonâ€™s disease: achievements and shortcomings. Expert Review of Neurotherapeutics, 2004, 4, 985-993.	2.8	16
87	The complexities of hormonal influences and risk of Parkinson's disease. Movement Disorders, 2014, 29, 845-848.	3.9	16
88	Knowledge of Parkinsonâ€™s Disease inÂaÂMultiethnic Urban Asian Setting. Journal of Parkinson's Disease, 2015, 5, 865-879.	2.8	16
89	The pill questionnaire in a nondemented Parkinson's disease population. Movement Disorders, 2012, 27, 1308-1311.	3.9	15
90	Understanding falls in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2017, 35, 75-81.	2.2	15

#	Article	IF	Citations
91	Understanding, Impact, and Communication of â€œOffâ€•Periods in Parkinson's Disease: A Scoping Review. Movement Disorders Clinical Practice, 2018, 5, 461-470.	1.5	15
92	Comparison of an Online-Only Parkinsonâ€™s Disease Research Cohort to Cohorts Assessed In Person. Journal of Parkinson's Disease, 2020, 10, 677-691.	2.8	15
93	Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. Alzheimer's and Dementia, 2023, 19, 226-243.	0.8	15
94	Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Movement Disorders, 2018, 33, 468-472.	3.9	14
95	Small molecule inhibitors of Î±-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Molecular Neurodegeneration, 2021, 16, 77.	10.8	13
96	Clustering of motor and nonmotor traits in leucineâ€rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. Movement Disorders, 2018, 33, 960-965.	3.9	12
97	Hypertension and progressive supranuclear palsy. Parkinsonism and Related Disorders, 2019, 66, 166-170.	2.2	12
98	Communication About OFF Periods in Parkinson's Disease: A Survey of Physicians, Patients, and Carepartners. Frontiers in Neurology, 2019, 10, 892.	2.4	12
99	A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. Movement Disorders, 2009, 24, 2370-2378.	3.9	11
100	Atypical Antipsychotic Use and Parkinsonism in Dementia: Effects of Drug, Dose, and Sex. American Journal of Geriatric Pharmacotherapy, 2012, 10, 381-389.e3.	3.0	11
101	Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer. World Journal of Urology, 2017, 35, 1417-1423.	2.2	11
102	Cognitive Complaints in Nondemented Parkinsonâ€™s Disease Patients and Their Close Contacts do not Predict Worse Cognitive Outcome. Alzheimer Disease and Associated Disorders, 2019, 33, 147-153.	1.3	11
103	Using artificial intelligence to identify antiâ€hypertensives as possible disease modifying agents in Parkinson's disease. Pharmacoepidemiology and Drug Safety, 2021, 30, 201-209.	1.9	11
104	Current Knowledge on the Evolution of Care Partner Burden, Needs, and Coping in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 510-520.	1.5	11
105	Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease. Movement Disorders, 2021, 36, 2419-2425.	3.9	11
106	Level I <scp>PDâ€MCI</scp> Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia. Movement Disorders Clinical Practice, 2022, 9, 479-483.	1.5	11
107	Small and Large Magnetic Resonance Imagingâ€“Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. Movement Disorders, 2022, 37, 1304-1309.	3.9	11
108	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. Journal of Parkinson's Disease, 2018, 8, 131-139.	2.8	10

#	Article	IF	Citations
109	Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinsonâ€™s disease. Clinical Autonomic Research, 2019, 29, 603-614.	2.5	10
110	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. Parkinsonism and Related Disorders, 2020, 80, 127-132.	2.2	10
111	Disparities in Deep Brain Stimulation Use for Parkinsonâ€™s Disease in Ontario, Canada. Canadian Journal of Neurological Sciences, 2020, 47, 642-655.	0.5	10
112	LRRK2 and Parkin mutations in a family with parkinsonismâ€”Lack of genotypeâ€“phenotype correlation. Neurobiology of Aging, 2010, 31, 721-722.	3.1	9
113	Parkinson disease with mild cognitive impairment: Domainâ€specific cognitive complaints predict dementia. Acta Neurologica Scandinavica, 2020, 142, 585-596.	2.1	9
114	Variations in hospitalization rates across Parkinson's Foundation Centers of Excellence. Parkinsonism and Related Disorders, 2020, 81, 123-128.	2.2	9
115	Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation. Journal of Visualized Experiments, 2020, , .	0.3	9
116	Triggers and alleviating factors for fatigue in Parkinsonâ€™s disease. PLoS ONE, 2021, 16, e0245285.	2.5	9
117	Genetics Meets Environment: Evaluating Geneâ€“Environment Interactions in Neurologic Diseases. Seminars in Neurology, 2011, 31, 553-562.	1.4	8
118	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. Neurobiology of Aging, 2021, 105, 378.e1-378.e9.	3.1	8
119	Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. Genetics in Medicine, 2014, 16, 644-645.	2.4	7
120	Independent application of montreal cognitive assessment/mini-mental state examination conversion. Movement Disorders, 2015, 30, 1710-1711.	3.9	7
121	The experience of care partners of patients with Parkinsonâ€™s disease psychosis. PLoS ONE, 2021, 16, e0248968.	2.5	7
122	Current Use of Domperidone and Co-prescribing of Medications that Increase Its Arrhythmogenic Potential Among Older Adults: A Population-Based Cohort Study in Ontario, Canada. Drugs and Aging, 2014, 31, 805-813.	2.7	6
123	The financial burden of prescription drugs for neurological conditions in Canada: Results from the National Population Health Study of Neurological Conditions. Health Policy, 2017, 121, 389-396.	3.0	6
124	Anti-inflammatory drug use and progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 48, 89-92.	2.2	6
125	We are what we eat â€” editorsâ€™ note on the role of diet in Parkinson's disease. Movement Disorders, 2019, 34, 1-1.	3.9	6
126	Experience and Impact of OFF Periods in Parkinsonâ€™s Disease: A Survey of Physicians, Patients, and Carepartners. Journal of Parkinson's Disease, 2020, 10, 315-324.	2.8	6

#	Article	IF	Citations
127	Reluctance to start medication for Parkinson's disease: A mutual misunderstanding by patients and physicians. Parkinsonism and Related Disorders, 2014, 20, 608-612.	2.2	5
128	Brain tissue pulsatility is related to clinical features of Parkinson's disease. NeuroImage: Clinical, 2018, 20, 222-227.	2.7	5
129	Clinical and Economic Outcomes Associated with Dysphagia in Hospitalized Patients with Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 1965-1971.	2.8	5
130	Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial. Movement Disorders, 2022, , .	3.9	5
131	A 21â€Year Retrospective Study of the Toronto Western Hospital Deep Brain Stimulation Cohort. Movement Disorders, 2018, 33, 850-852.	3.9	4
132	Antipsychotic Drug Dispensing in Older Adults With Parkinsonism. American Journal of Geriatric Psychiatry, 2018, 26, 1244-1257.	1.2	4
133	The experience of off periods: Qualitative analysis of interviews with persons with Parkinson's and carepartners. Clinical Parkinsonism & Related Disorders, 2019, 1, 31-36.	0.9	4
134	<scp>Ageâ€Related</scp> Parkinsonian Signs in Microdeletion 22q11.2. Movement Disorders, 2020, 35, 1239-1245.	3.9	4
135	Understanding the Lexicon of Fatigue in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 1185-1193.	2.8	4
136	Survival and Health Care Use After Deep Brain Stimulation for Parkinsonâ€™s Disease. Canadian Journal of Neurological Sciences, 2021, 48, 372-382.	0.5	4
137	Knowledge, Responsibilities, and Peer Advice From Care Partners of Patients With Parkinson Disease Psychosis. Frontiers in Neurology, 2021, 12, 633645.	2.4	4
138	Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases. GeroScience, 2022, 44, 1575-1598.	4.6	4
139	The Danger of Not Treating Parkinson Disease Psychosisâ€”Reply. JAMA Neurology, 2016, 73, 1156.	9.0	3
140	Survival in Restless Legs Syndrome: An 11-Year Surveillance, Community-Based Population Study. Neuroepidemiology, 2020, 54, 375-382.	2.3	3
141	Impact of Off Periods on Persons With Parkinson Disease and Care Partners. Neurology: Clinical Practice, 2021, 11, e232-e238.	1.6	3
142	Demographic Influences on the Relationship Between Fatigue and Quality of Life in Parkinson's Disease. Movement Disorders Clinical Practice, 2022, 9, 76-81.	1.5	3
143	Caregiving concerns and clinical characteristics across neurodegenerative and cerebrovascular disorders in the Ontario neurodegenerative disease research initiative. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	3
144	Epidemiological Evidence for an Immune Component of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, S29-S43.	2.8	3

#	Article	IF	Citations
145	Piecing together the puzzle of progression and mortality in Parkinson's disease. British Journal of Clinical Pharmacology, 2012, 74, 264-266.	2.4	2
146	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. Movement Disorders, 2018, 33, 499-500.	3.9	2
147	Beta Agonists and Progression of Parkinson's Disease in Older Adults: A Retrospective Cohort Study. Movement Disorders, 2020, 35, 1275-1277.	3.9	2
148	Progressive Supranuclear Palsy and Statin Use. Movement Disorders, 2020, 35, 1253-1257.	3.9	2
149	Use of Figurative Language by People With Parkinson Disease to Describe â€œOffâ€•Periods. Neurology: Clinical Practice, 2021, 11, e462-e471.	1.6	2
150	The Experience of OFF Periods in Parkinsonâ€™s Disease: Descriptions, Triggers, and Alleviating Factors. Journal of Patient-centered Research and Reviews, 2021, 8, 232-238.	0.9	2
151	Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinsonâ€™s disease. Clinical Autonomic Research, 2021, 31, 729-736.	2.5	2
152	Surveying Global Availability of Parkinsonâ€™s Disease Treatment. Journal of Parkinson's Disease, 2022, 12, 1023-1034.	2.8	2
153	69-Year-old man with gait disturbance and parkinsonism. Movement Disorders, 2001, 16, 548-561.	3.9	1
154	Reply letter to Jinnah â€œLocus pocusâ€•and Albanese â€œComplex dystonia is not a category in the new 2013 consensus classificationâ€: Necessary evolution, no magic!. Movement Disorders, 2016, 31, 1760-1762.	3.9	1
155	Gene-Environment Interactions in Progressive Supranuclear Palsy. Frontiers in Neurology, 2021, 12, 664796.	2.4	1
156	Reply: Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: Need for longâ€term clinical trials. Movement Disorders, 2011, 26, 1371-1371.	3.9	0
157	Cochrane Review: Pimozide for tics in Tourette's syndrome. Evidence-Based Child Health: A Cochrane Review Journal, 2011, 6, 240-254.	2.0	0
158	Nonmotor series. Movement Disorders, 2016, 31, 1079-1079.	3.9	0
159	<scp>W</scp>hat <scp>W</scp>ould <scp>D</scp>r. <scp>J</scp>ames <scp>P</scp>arkinson <scp>T</scp>hink <scp>T</scp>oday <scp>III</scp>: <scp>M</scp>easuring <scp>H</scp>ealthâ€<scp>R</scp>elated <scp>Q</scp>uality of <scp>L</scp>ife. Movement Disorders, 2017, 32, 364-365.	3.9	0
160	Reply to â€œStudying reproducibility of data-driven Parkinson's disease subtypesâ€: Parkinsonism and Related Disorders, 2019, 66, 245-246.	2.2	0
161	Reply to â€˜Neuropathological progression of clinical Parkinson disease subtypesâ€™. Nature Reviews Neurology, 2019, 15, 361-362.	10.1	0
162	Clinical Followâ€up of Parkinson's Disease With Newly Prescribed Quetiapine. Movement Disorders, 2020, 35, 1690-1692.	3.9	0

#	Article	IF	Citations
163	Heart rate variability biomarkers of leucine-rich repeat kinase 2-associated Parkinson's disease. , 2020, , .		0
164	Huntingtonâ€™s Disease and Hypertension: Sorting Out Mixed Messages. Movement Disorders, 2020, 35, 915-917.	3.9	0
165	Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3â€‰Years in Patients with Early Parkinson's Disease. Movement Disorders, 2021, 36, 1979-1983.	3.9	0